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ABSTRACT The APPLE COPD-ICON2 trial is a prospective 2×2 factorial, double-blinded proof-of-concept
randomised controlled trial targeting patients with chronic obstructive pulmonary disease (COPD) without prior
history of cardiovascular disease. The primary goal of this trial is to investigate if treatment with antiplatelet therapy
will produce the predefined cut-off of platelet inhibition measured using the Multiplate test in COPD patients.
Eligible patients were randomised to aspirin plus placebo, ticagrelor plus placebo, aspirin plus ticagrelor
or placebo only for 6 months. The primary outcome comprises inhibition (binary response) of arachidonic
acid- (ASPI test, cut-off <40) and adenosine diphosphate- (ADP test, cut-off <46) induced platelet
aggregation at 6 months.
543 patients were screened and 120 patients were recruited with mean age of 67.5 years; 47.5% patients
were male. The per-protocol ASPI test response rate to aspirin was 68.3% (95% CI 52.3–80.9%). The per-
protocol ADP test response rate to ticagrelaor was 68.8% (95% CI 50.4–82.6%).
Platelet response to antiplatelet therapy with aspirin and ticagrelor was not observed in nearly one-third
of COPD patients without prior history of cardiovascular disease. These findings support the high pro-
thrombotic milieu and the need for further research to determine the effect of antiplatelet/antithrombotic
therapy on cardiovascular morbidity and mortality in COPD patients.
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COPD is the world’s number 2 killer. In our study, treatment with antiplatelet therapy in COPD
patients did not lead to adequate platelet response in just under a third of patients, emphasising
the high thrombotic milieu in these patients. http://bit.ly/2WT8241
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Introduction
Chronic obstructive pulmonary disease (COPD) is a significant global health burden [1] and is in the world’s
top three global killers. The major cause of COPD is smoking and there is an excess of cardiovascular disease
seen in COPD patients as compared to those matched for smoking exposure without COPD. The prevalence
of coronary artery disease (CAD) in COPD patients has been estimated at 10–38% [2, 3] with 20–50% of
mortality in COPD being related to cardiovascular causes [4, 6–] The ECLIPSE (Evaluation of COPD
Longitudinally to Identify Predictive Surrogate Endpoints) observational cohort study showed that the
presence of CAD in patients with COPD is associated with poor clinical outcomes [7].
Several mechanisms have been proposed to explain the increased risk of CAD in COPD patients. Spill-over
of pulmonary inflammation to the systemic circulation has been proposed as a possible mechanism.
Another proposed mechanism contributing to CAD in COPD is an increased in vivo platelet activation
state, which plays a key role in the pathogenesis of atherothrombosis. Monocyte–platelet aggregates, a
marker of platelet activation, are elevated in both patients with stable and acute exacerbation of COPD [8].
The use of aspirin in the primary prevention among individuals without cardiovascular disease has been
shown to be associated with a lower risk of cardiovascular events and an increased risk of major bleeding
[9]. Ticagrelor has been used in primary prevention among type 2 diabetic patients in the THEMIS (The
Effect of Ticagrelor on Health Outcomes in Diabetes Mellitus Patients Intervention Study) trial [10].
Preliminary results showed that ticagrelor taken in conjunction with aspirin showed a statistically
significant reduction in a composite of major adverse cardiovascular events compared to aspirin alone.
The role of antiplatelet therapy (APT) using aspirin and ticagrelor in the primary prevention of
cardiovascular disease among COPD patients has not been evaluated previously. The aim of this
early-phase trial is to evaluate the effect of antiplatelet therapy (aspirin, ticagrelor) on platelet function and
explore its effect on the inflammatory markers in patients with COPD with no prior history of CAD.
Methods
Trial design
The APPLE COPD trial is a single-centre, early-phase, 2×2 factorial, double-blind randomised controlled
trial. Investigators/assessors and patients were blinded through the use of matched placebo tablets. The
early-phase design allows decision-making regarding the further investigation of either aspirin or ticagrelor
in late-phase trials. Full details of the trial design and analysis plan have been published previously [11].
Eligibility criteria specified that patients were aged ⩾18 years, with ⩾10 pack-years smoking history,
confirmed airflow limitation on spirometry (forced expiratory volume in 1 s (FEV1) <80% predicted and
FEV1/forced vital capacity (FVC) ratio 0.7) and had given written informed consent. Exclusion criteria for
the study included any condition concurrently treated through anticoagulation or APT, including aspirin
or ticagrelor; specific contraindications to management with antiplatelet medication; or aspirin and
ticagrelor use. The trial was carried out in accordance with the Declaration of Helsinki. The regional
National Health Service (NHS) research ethics committee (REC15/NE/0155) gave approval for this trial.
Trial interventions
Consenting patients were randomised using the Newcastle Clinical Trials Unit secure web-based system to
ensure concealment of allocation, and allocated in a double-blind manner into one of four groups (aspirin
plus placebo, ticagrelor plus placebo, aspirin plus ticagrelor (dual antiplatelet therapy (DAPT)) or placebo
only) using permuted random blocks of variable length, stratified by age (⩽65 years, >65 years). Aspirin
(75 mg) was administered once daily dose and ticagrelor (90 mg) twice daily for a 6-month period,
provided as two 3-month supplies. Compliance to medication was assessed at 1 month, 3 months and
6 months by the research team members in the research clinic.
Outcome measures
The primary outcome measure consisted of inhibition (binary response, yes/no) of the ASPI test with a
responder cut-off <40 for patients randomised to aspirin, and the adenosine diphosphate (ADP) test with
a responder cut-off <46 for patients randomised to ticagrelor. Platelet aggregation induced by ADP (ADP
test) or arachidonic acid (ASPI test) was assessed by whole-blood impedance aggregometry using the
Multiplate device (Roche Diagnostics, Burgess Hill, UK). The ASPI test is sensitive to an inhibition of the
platelet cyclo-oxygenase, which is the target of aspirin, and the ADP test is sensitive to inhibition of P2Y12,
which is the target of ticagrelor.
Secondary outcome measures were changes in systemic inflammatory markers including fibrinogen,
high-sensitivity C-reactive protein (hsCRP), tumour necrosis factor (TNF)-α, interleukin (IL)-6,
myeloperoxidase (MPO) from baseline to 6 months; changes in carotid intima media thickness and
non-invasive measures of vascular stiffness (pulse wave velocity) from baseline to 6 months; and changes
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in quality of life at baseline and at 6 months were evaluated using questionnaires (Euroqol five dimensions,
five levels (EQ5D-5L), St George’s Respiratory Questionnaire for COPD Patients (SGRQ-C)). In addition,
we recorded subjective reports of breathlessness using the Medical Research Council Dyspnoea (MRCD)
scale. The primary safety measure was the rates of major and minor bleeding as defined by the BARC
(Bleeding Academic Research Consortium) definition [12]. In addition, given that ticagrelor is associated
with dyspnoea, assumed to be due to its adenosine-mediated effects, we monitored FEV1, FVC and
MRCD scale as a safety outcome measure. All non-serious adverse reactions were recorded at 6-month
follow-up, and serious adverse events were recorded throughout the duration of the trial until 4 weeks
after trial therapy was stopped.
Statistical considerations
A Fleming–A’Hern [13] early-phase design was used to investigate the roles of each intervention (aspirin,
ticagrelor) in achieving a minimum level of response at 6 months worthy of further investigation. PERL
et al. [14] reported a response rate for ticagrelor and prasugrel at 1 month of 100% and 91.3%, respectively
in a non-randomised comparison in patients with myocardial infarction. APPLE COPD assumed a
response rate to reject either treatment (p0) <65% and a response rate to investigate either treatment
further (p1) >80%. The justification to investigate either treatment further is based on observing a critical
number of responses for each intervention, specifically 44 for aspirin and 42 for ticagrelor according to the
Fleming–A’Hern design. The control arm provides a direct and unbiased benchmark.
With error levels of 12% α (type 1) and 12% β (type 2), inflated due to the early-phase nature of the
design, the target recruitment was 50 patients per arm for each comparison within the 2×2 design, namely
1) aspirin versus no aspirin; 2) ticagrelor versus no ticagrelor. The sample size was adjusted for an
anticipated 15% drop-out rate within the 6-month timeframe to a target recruitment of 120 patients.
As a 2×2 factorial design, the primary analyses are based on a comparison of aspirin versus no aspirin and
ticagrelor versus no ticagrelor. Response rate was calculated on an intention to treat (ITT) basis as the total
number of patients responding at 6 months as a proportion of all patients randomised, reported as an
unadjusted odds ratio with 95% confidence intervals. A preplanned sensitivity analysis was carried out on
the per-protocol set removing patients who have withdrawn completely, were lost to follow-up or who
discontinued treatment. Adverse events are reported descriptively in terms of the number of events and
number of unique patients experiencing an adverse event expressed as a proportion of the total number of
patients starting treatment. Descriptive data are presented for demographics and baseline characteristics.
Results
Baseline characteristics
120 patients were recruited. The CONSORT (Consolidated Standards of Reporting Trials) diagram is
shown in figure 1. Patient characteristics were balanced across arms (table 1 and supplementary table S1).
The mean age of patients was 67.5 years and 57 (47.5%) patients were male. The median QRISK2 score
was 22.0 (interquartile range (IQR) 15.5–29.0). Of the 117 patients with current COPD medication
information, 88 (75.2%) were on triple inhaled therapy (inhaled corticosteroid (ICS)/long-acting β-agonist
(LABA)/long-acting muscarinic antagonist), 12 (10.3%) were on ICS/LABA, 11 (9.4%) were on LABA
alone, nine (7.7%) were on long-term azithromycin and four (3.4%) were on long-term oxygen. The
laboratory tests and other study related variables are shown in table 2 and supplementary table S2.
Treatment received
All 120 randomised patients started treatment. The median (IQR) time on treatment from randomisation
across all arms was 182 (175–189) days (supplementary table S3). Treatment compliance was high, with
91% and 88% of the 102 participants who reached 6 months taking ⩾80% of the protocol dose for aspirin/
placebo aspirin and ticagrelor/placebo ticagrelor, respectively (supplementary table S4).
Primary outcome measure
The ITT and per-protocol analysis of the primary outcome measure is shown in table 3. In the 60 patients
randomised to aspirin, at 6 months, there were 29 (48.3%, 95% CI 35.8–61.0%) ASPI responders observed
in the ITT analysis. This rate is lower than anticipated in the statistical design and did not reach the
critical threshold of 44 responders required to warrant further research, according to the Fleming–A’Hern
design. In the 58 patients randomised to ticagrelor, there were 24 (41.4%, 95% CI 29.3–54.6%) ADP
responders observed in the ITT analysis. This rate is lower than anticipated in the design and did not
reach the critical threshold of 42 responders required to warrant further research. Figure 2a shows a
reduction in ASPI from baseline in the aspirin group at 1 month and 6 months, but no reduction in the
no aspirin group. There was more variation in the aspirin group at 6 months as shown by the IQR. A
reduction in ADP is observed in the ticagrelor group at 1 and 6 months compared to baseline. This
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Assessed for eligibility
(n=543)
Enrolment
Allocation
Follow-up
Analysis
Randomised (n=120)#Observational (n=1)
Eligibile but not randomised (n=173)
 Clinician's decision (n=9)
 Logistical reasons (n=4)
 Patient missed (n=1)
 Decline (n=88)
 DNA (n=58)
 Eligible not contacted (n=1)
 DNAed CRF ×3 (n=2)
 Uncontactable (n=10)
Placebo (n=31)
 Received allocated
   intervention (n=31)
Ineligibile (n=249)
 Concurrently treated through 
 anticoagulation/antiplatelet therapy   
 (n=167)
 Other specific contraindications (n=38)
 Any contraindication for aspirin and
 ticagrelor use (n=15)
 Life expectancy <1 year (n=13)
 Current involvement in another trial (n=6)
 COPD with atypical cause (n=2)
 Unable to provide informed consent (n=5)
 Not COPD (n=3)
Aspirin (n=31)
 Received allocated
   intervention (n=31)
Ticagrelor (n=29)
 Received allocated
   intervention (n=29)
DAPT (n=29)
 Received allocated
   intervention (n=29)
ITT dataset (n=31)
Primary outcome data 
  (n=27)¶
PP dataset (n=26)
ITT dataset (n=31)
Primary outcome data 
  (n=28)
PP dataset (n=28)
ITT dataset (n=29)
Primary outcome data 
  (n=23)
PP dataset (n=19)
ITT dataset (n=29)
Primary outcome data 
  (n=23)
PP dataset (n=13)
Lost to follow-up by
6 months (n=3)
 Death (n=1)
 Complete withdrawal
 due to non-compliance
 with visits/drug or
 inability to attend visits
 (n=2)
Discontinued intervention
by 6 months (n=2)
 Participants decided  
 they no longer wanted  
 to participate (n=1)
 Breathlessness (n=1)
Lost to follow-up by
6 months (n=3)
 Complete withdrawal
 due to non-compliance
 with visits/drug or
 inability to attend visits
 (n=3)
Discontinued intervention
by 6 months (n=0)
Lost to follow-up by
6 months (n=6)
 Complete withdrawal
 (n=5)
  Breathlessness (n=1)
  Exacerbation of   
  COPD (n=1)
  Non-compliance with 
  visits/drug or inability  
  to attend visits (n=1)
  Participant decided  
  they no longer   
  wanted to participate  
  (n=2)
 Unknown (n=1)
Discontinued intervention 
by 6 months (n=4)
 Breathlessness (n=3)
 Diarrhoea (n=1)
 
Lost to follow-up by
6 months (n=6)
 Death (n=1)
 Complete withdrawal
 (n=4)
  Breathlessness (n=2)
  Participant decided
  they no longer wanted  
  to particpate (n=2)
 Unknown (n=1)
Discontinued intervention 
by 6 months (n=10)
 Headaches and   
 insomnia (n=1)
 Bruising (n=1)
 Breathlessness (n=5)
 Developed stable   
 angina (n=1)
 Allergic rash (n=1)
 Other (n=1) 
FIGURE 1 CONSORT (Consolidated Standards of Reporting Trials) diagram. COPD: chronic obstructive pulmonary disease; DAPT: dual antiplatelet
therapy; ITT: intention-to-treat; PP: per-protocol. #: there was one administrative error, so there were 121 randomisations, of which 120 were
related to patients; ¶: one patient attended visit but the lab samples were not suitable for analysis.
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reduction was not seen in the no-ticagrelor group. There is larger variation in the ADP score at 6 months
in the ticagrelor group (figure 2b).
As a prespecified sensitivity analysis, we calculated the rate of response on a per-protocol analysis set
consisting of 86 (72%) of the 120 randomised participants (figure 1). In the aspirin group there were 28
(68.3%, 95% CI 52.3–80.9%) ASPI responders observed (table 3). In the ticagrelor group there were 22
(68.8%, 95% CI 50.4–82.6%) ADP responders observed. The larger variation in response at 6 months
compared to 1 month is reduced for both the aspirin and ticagrelor groups when the data is summarised
on the per-protocol analysis set (figure 3). Supplementary figure S1 shows that the larger variability
present in the aspirin and ticagrelor groups is from the DAPT arm.
Secondary outcome measures
There were no observed differences between the groups in the changes in quality of life using
questionnaires (EQ5D-5L, SGRQ-C) from baseline to 6 months (figures 4 and 5, respectively). There were
no clinically significant differences in changes in inflammatory markers including fibrinogen, hsCRP,
TNF-α, IL-6 and MPO from baseline to 6 months and there were no clinically significant differences in
changes in carotid intima media thickness and non-invasive measures of vascular stiffness from baseline to
6 months in the different groups (supplementary figures S2, S3, S4).
Safety outcomes
Five type 1 bleeds according to the BARC criteria were recorded in this study: two in the placebo arm, two
in the aspirin arm and one in the ticagrelor arm. They were all categorised as minimal on the
Thrombolysis in Myocardial Infarction scale (supplementary table S5). Dyspnoea was measured using the
TABLE 1 Baseline characteristics
Placebo Aspirin Ticagrelor DAPT Total
Subjects 31 31 29 29 120
Age at randomisation 66.3±9.2 68.5±7.2 66.5±7.7 69.0±10.6 67.5±8.7
Male 15 (48) 12 (39) 15 (52) 15 (52) 57 (47.5)
QRISK2 score % 20 (12–28) 19 (17–27) 22 (14–27) 24 (20–35) 22.0 (15.5–28.0)
Smoking status
Nonsmoker 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Ex-smoker 21 (68) 20 (65) 21 (72) 21 (72) 83 (69.2)
Light smoker (<10 pack-years) 3 (10) 0 (0) 1 (3) 3 (10) 7 (5.8)
Moderate smoker (10–19 pack-years) 5 (16) 9 (29) 5 (17) 4 (14) 23 (19.2)
Heavy smoker (⩾20 pack-years) 2 (6) 2 (6) 2 (7) 1 (3) 7 (5.8)
Diabetes status
Type 1 0 (0) (0) 2 (7) 3 (10) 5 (4.2)
Type 2 2 (6) 3 (10) 2 (7) 3 (10) 10 (8.3)
Angina or heart attack in a first-degree relative aged <60 years?
Yes
10 (32) 6 (19) 7 (24) 9 (31) 32 (26.7)
On blood pressure treatment? Yes 10 (32) 9 (29) 12 (41) 13 (45) 44 (36.7)
Rheumatoid arthritis? Yes 0 (0) 1 (3) 3 (10) 1 (3) 5 (4.2)
Cholesterol/HDL ratio 3.0
(2.2–4.0)
2.8
(2.4–4.1)
3.0
(2.6–3.6)
3.1
(2.4–3.6)
2.9 (2.4–3.8)
Systolic blood pressure mmHg 145.7 (16.1) 144.6 (18.2) 143.1 (14.7) 144.5 (22.1) 144.5 (17.7)
Height cm 167.5 (9.9) 163.0 (10.5) 164.6 (11.3) 166.9 (10.9) 165.5 (10.7)
Weight cm 74.7 (18.2) 73.1 (17.4) 72.2 (18.7) 79.9 (18.5) 74.9 (18.2)
BMI kg·m−2 26.5 (5.4) 27.4 (5.6) 26.5 (5.7) 28.9 (7.0) 27.3 (6.0)
COPD disease category#
Severe (FEV1 <30% pred) 8 (27) 6 (19) 6 (21) 5 (17) 25 (21.0)
Moderate (FEV1 30–49% pred) 10 (33) 14 (45) 7 (24) 11 (38) 42 (35.3)
Mild (FEV1 50–79% pred) 12 (40) 11 (35) 16 (55) 13 (45) 52 (43.7)
Daily sputum producer >3 months in each of last 2 year? Yes 22 (71) 15 (48) 18 (62) 15 (52) 70 (58.3)
Number of acute exacerbations of COPD treated in past
12 months
4.2 (4.5) 3.4 (3.1) 2.6 (3.1) 2.5 (2.0) 3.2 (3.3)
Number of hospitalisation in past 12 months for COPD 0.6 (1.2) 0.4 (1.6) 0.4 (0.9) 0.2 (1.0) 0.4 (1.2)
Data are presented as n, mean±SD, n (%) or median (interquartile range). DAPT: dual antiplatelet therapy; HDL: high-density cholesterol; BMI: body
mass index; COPD: chronic obstructive pulmonary disease; FEV1: forced expiratory volume in 1 s. #: National Institute for Health and Care
Excellence Clinical guideline ( June 2010).
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MRCD scale, where a score of 1 equates to minimal breathlessness and 5 equates to housebound due to
breathlessness. The MRCD score was similar across the groups and at all time points. This was also the
case for FEV1 and FVC (supplementary table S6).
Adverse events and serious adverse events
The adverse events are shown in supplementary table S7. During the study, one participant, who was in
the DAPT arm, experienced a severe adverse event that was considered to be definitely treatment related.
This adverse event was breathlessness and the treatment was discontinued. There were 31 serious adverse
events in 10 patients (8%, n=120), none of which were considered to be related to treatment
(supplementary table S8).
Discussion
Increasingly it is accepted that COPD is a complex multisystems disorder [15]. In addition to
neuropsychiatric morbidity, metabolic syndrome, obesity and diabetes, COPD has been shown to be linked
with systemic inflammation, thrombocytosis and activation of prothrombotic pathways [16]. The end
result of these is an elevated risk of CAD. However, to date there are few studies specifically targeting the
excess CAD risk in COPD patients. Cardiovascular complications in COPD are one of the most costly
comorbidities [17].
Our data are novel in that they demonstrate in the per-protocol analysis that just over two-thirds of
patients with COPD demonstrated platelet response to antiplatelet therapies compared to 100% of patients
TABLE 2 Laboratory and other secondary outcomes data
Placebo Aspirin Ticagrelor DAPT Total
Subjects 31 31 29 29 120
Haemoglobin g·L−1 146.4±13.3 145.4±14.5 146.1±13.0 141.8±16.6 144.9±14.4
White blood cell count ×109 cells·L−1 8.6±2.6 8.6±2.3 8.8±2.2 8.3±1.9 8.6±2.2
Platelet count ×109 cells·L−1 284.3±77.2 280.6±61.0 284.9±65.7 281.6±71.8 282.9±68.4
Neutrophil count ×109 cells·L−1 5.7±2.3 5.6±2.0 5.6±1.8 5.3±1.8 5.2 (4.3–6.4)
Monocytes ×109 cells·L−1 0.73±0.42 0.64±0.21 0.70±0.19 0.67±0.23 0.60 (0.50–0.80)
Eosinophil count ×109 cells·L−1 0.24±0.17 0.20±0.15 0.18±0.12 0.24±0.19 0.19 (0.11–0.31)
Urea mmol·L−1 4.7±1.2 5.4±2.1 5.0±2.3 5.9±1.8 5.2±1.9
Creatinine µmol·L−1 76.1±14.9 71.4±14.0 76.1±20.0 86.9±19.2 77.5±17.9
Fibrinogen g·L−1 3.9±0.8 3.7±0.7 3.9±0.8 3.7±0.9 4.0 (3.0–4.0)
hsCRP mg·L−1 7.8±15.4 3.6±3.5 8.2±16.5 3.8±3.8 2.5 (1.2–5.6)
TNF-α pg·mL−1 2.38±2.73 2.35±2.59 1.52±1.23 1.44±1.50 1.00 (0.70–2.14)
IL-6 pg·mL−1 5.81±5.64 5.96±6.18 3.82±3.04 3.39±1.61 3.43 (2.26–5.20)
MPO ng·mL−1 814.38±480.4 1013.17±578.5 785.53±453.5 702.53±324.3 773.63 (420.40–1173.66)
Vascular stiffness m·s−1 9.74±1.90 9.91±2.49 9.23±1.23 9.87±2.58 9.69±2.11
CIMT maximum mm 1.0±0.2 1.0±0.3 1.0±0.2 1.0±0.2 1.0±0.2
MRC dyspnoea scale 3.6±1.0 3.7±1.1 3.4±1.3 3.3±1.2 3.5±1.1
1 0 (0) 1 (3) 3 (10) 2 (7) 6 (5.0)
2 7 (23) 4 (13) 4 (14) 7 (24) 22 (18.3)
3 4 (13) 6 (19) 6 (21) 4 (14) 20 (16.7)
4 15 (48) 13 (42) 10 (34) 12 (41) 50 (41.7)
5 5 (16) 7 (23) 6 (21) 4 (14) 22 (18.3)
EQ5D-5L index 0.619±0.261 0.676±0.222 0.662±0.221 0.675±0.253 0.658±0.238
EQ5D health score 61.8±20.4 59.3±16.6 66.6±18.1 60.9±17.5 62.1±18.2
SGRQ-C current health
Very good 2 (6) 0 (0) 0 (0) 0 (0) 2 (1.7)
Good 4 (13) 5 (17) 10 (34) 8 (28) 27 (22.7)
Fair 18 (58) 18 (60) 12 (41) 14 (48) 62 (52.1)
Poor 4 (13) 7 (23) 6 (21) 6 (21) 23 (19.3)
Very poor 3 (10) 0 (0) 1 (3) 1 (3) 5 (4.2)
SGRQ-C symptom score 73.6±22.2 72.3±18.4 60.2±24.8 67.3±19.7 68.5±21.8
SGRQ-C activity score 74.2±27.3 74.8±24.6 67.7±24.2 62.8±30.8 70.1±27.0
SGRQ-C impact score 45.2±26.7 42.5±20.1 40.0±25.2 42.2±27.2 42.5±24.7
SGRQ-C total 59.1±23.9 57.7±19.1 53.0±21.8 53.0±25.2 55.8±22.5
Data are presented as n, mean±SD, median (interquartile range) or n (%). DAPT: dual antiplatelet therapy; hsCRP: high-sensitivity C-reactive
protein; TNF: tumour necrosis factor; IL: interleukin; MPO: myeloperoxidase; CIMT: carotid intima media thickness; MRC: Medical Research
Council; SGQR-C: St George’s Respiratory Questionnaire for COPD patients.
https://doi.org/10.1183/23120541.00110-2019 6
COPD | V. KUNADIAN ET AL.
with myocardial infarction [14]. Interestingly, we noted that for both ASPI and ADP tests >30% of
patients in the per-protocol analysis did not demonstrate platelet response to therapeutic targeting based
on recognised thresholds in the primary prevention setting in our population. High on-treatment platelet
reactivity despite use of P2Y12 antagonists is associated with adverse cardiac events [18]. A previous study
in the setting of secondary prevention showed that COPD patients who underwent percutaneous coronary
intervention have higher “on treatment” platelet reactivity compared to non-COPD patients and suggested
that this could contribute to the high cardiovascular mortality in these patients [19]. Reassuringly, our
data demonstrate that there were mean response rates in ADP and ASPI tests that were very similar at
1 month and 6 months, suggesting that the effects were sustained.
We noted more withdrawals in those treated with ticagrelor than those treated with aspirin alone or
placebo. Despite the significant airflow limitation seen in this group only one patient had an adverse event
reported as severe breathlessness requiring drug discontinuation. The withdrawal rates were higher in the
TABLE 3 Primary outcome measures
Aspirin No aspirin Ticagrelor No ticagrelor
ITT analysis set# 60 60 58 62
Baseline 1 6 4 1
1.7 (0.2–11.3) 10 (4.5–20.8) 6.9 (2.6–17.3) 1.6 (0.2–10.9)
6 months 29 7 24 2
48.3 (35.8–61) 11.7 (5.6–22.8) 41.4 (29.3–54.6) 3.2 (0.8–12.3)
PP analysis set¶ 41 45 32 54
6 months 28 7 22 2
68.3 (52.3–80.9) 15.6 (7.5–29.6) 68.8 (50.4–82.6) 3.7 (0.9–14.0)
Data are presented as n or % (95% CI). ITT: intention-to-treat; PP: per-protocol. #: descriptive statistics for
the primary outcome of response for the comparative groups at baseline and 6 months for the ITT analysis
set; ¶: response is ASPI response in the aspirin and no-aspirin columns and adenosine diphosphate
response in the ticagrelor and no-ticagrelor columns.
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FIGURE 2 Primary outcome measure intention-to-treat (ITT) analysis. Boxplots of the a) ASPI test split by no-aspirin and aspirin comparative
groups over time; b) adenosine diphosphate (ADP) test split by no-ticagrelor and ticagrelor comparative groups over time (ITT analysis set).
i) Baseline; ii) 1 month; iii) 6 months. The green dashed line indicates the threshold below which patients are considered to be responders.
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FIGURE 3 Primary outcome measure per-protocol analysis. Boxplots of the a) ASPI test split by no-aspirin and aspirin comparative groups over
time; b) adenosine diphosphate (ADP) test split by no-ticagrelor and ticagrelor comparative groups over time with patients who withdrew,
discontinued treatment or lost to follow-up by the timepoint of interest removed (per-protocol analysis set). i) Baseline; ii) 1 month; iii) 6 months.
The green dashed line indicates the threshold below which patients are considered to be responders.
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FIGURE 4 Secondary outcome measure St George’s Respiratory Questionnaire for chronic obstructive pulmonary disease patients (SGRQ-C).
Boxplots of SGRQ-C total score over time by comparative groups split by a) no aspirin and aspirin and b) no ticagrelor and ticagrelor
(intention-to-treat analysis set). i) Baseline; ii) 1 month; iii) 6 months.
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ticagrelor arms, but were similar to those reported in a previous study of ticagrelor where nearly 11% of
patients stopped therapy due to dyspnoea [20]. Nevertheless, we observed reduced platelet response in
patients receiving aspirin as well as those receiving ticagrelor, suggesting that this is a true reflection of
response not merely due to drug compliance in our COPD patients. Importantly, our further per-protocol
analysis (excluding patients who have withdrawn completely, were lost to follow-up or who discontinued
treatment) showed that >30% of patients did not demonstrate the required platelet response to antiplatelet
therapy.
Several commercially available validated tests are used to evaluate platelet response to therapy. In our study
we used the Multiplate test, which has previously been shown to be concordant with VerifyNow and
vasodilator stimulated phosphoprotein (VASP) tests. The Multiplate test has been shown to best reflect the
in vivo plasma concentrations of ticagrelor and its active metabolite compared to other tests (VerifyNow
and VASP) [21]. Other studies have shown Multiplate, VASP and platelet function analyser tests to have
moderate agreement regarding the classification of patients as responders to P2Y12 inhibition [22].
Therefore, the Multiplate test is a valid method of evaluating platelet response to antiplatelet therapy in
our patient cohort. Of note, platelet reactivity values have not been shown to be predictive of
cardiovascular morbidity and mortality [23]. Our study was not designed to evaluate cardiovascular
morbidity and mortality.
One of the key concerns in initiating antiplatelet therapy in primary prevention is bleeding. We specifically
sought known side-effects of antiplatelet therapy such as bleeding (aspirin and ticagrelor) and dyspnoea
(ticagrelor). In our study we did not identify any clinically significant bleeding in patients receiving
antiplatelet therapy. This might be due to the fact that our study had small number of patients and were
treated with antiplatelet therapy for 6 months. Previous studies have shown that ticagrelor-related
dyspnoea is usually mild or moderate in intensity and does not appear to be associated with differences
concerning any efficacy or safety outcomes with ticagrelor compared with clopidogrel therapy [24]. In our
study we did not observe clinically significant dyspnoea in our patient cohort. These findings support the
safety of using antiplatelet therapy in the primary prevention in patients with COPD. In a previous post
hoc analysis, COPD patients experienced high rates of ischaemic events compared to non-COPD patients.
Ticagrelor versus clopidogrel substantially decreased the absolute risk of ischaemic events (5.8%) in COPD
patients, without increasing overall major bleeding events [25]. Based on previous studies, we anticipated a
close to 100% platelet response to ticagrelor in our patient cohort. However, this was not demonstrated in
our study. These findings support the high prothrombotic milieu in COPD patients, where in addition to
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FIGURE 5 Secondary outcome measure Euroqol five-dimensions (EQ5D) health score over time by comparative groups split by a) no aspirin and
aspirin and b) no ticagrelor and ticagrelor (intention-to-treat analysis set). i) Baseline; ii) 1 month; iii) 6 months.
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potent antiplatelet therapy, an antithrombotic therapy might be beneficial in addressing the excess
cardiovascular morbidity and mortality. Of note, although several serious adverse events were recorded in
our study, reassuringly none of these events were related to the drugs utilised in our study as such.
There were no improvements or decrements in the quality of life responses on antiplatelet therapy raising
the potential for long-term studies. Of note, in a previous study, short-term administration of high doses
of ticagrelor did not appear to alter pulmonary function at rest and during exercise in subjects at risk of
(healthy elderly) or with respiratory impairment (mild asthma or mild-to-moderate COPD) [26].
Neurohormonal activation and systemic inflammation have been suspected to play a significant role in
increasing the risk of cardiovascular disease [27, 29]. Ticagrelor as compared to clopidogrel is superior in
improving surrogate markers of endothelial function and on-treatment platelet reactivity [30]. In our
study, antiplatelet therapy did not have any clinically significant effect on any of the secondary outcome
measures including inflammatory biomarkers.
Strengths and limitations
The strengths of our study included the recruitment of patients with COPD who were representative of a
secondary care cohort with many patients with severe airflow limitation and multiple comorbidities. The
average QRISK2 score was >20%, confirming the fact that increased cardiovascular risk is prevalent in this
population.
Our study is limited by small sample size and short duration of antiplatelet therapy. However, although
this sample is not powered to address hard end-points, it is sufficiently powered to detect differences in
platelet reactivity between the groups. In our study we specifically included patients without prior history
of cardiovascular disease. Use of antiplatelet therapy has already been studied in patients with COPD and
cardiovascular disease. There is no consensus on the optimal duration to assess antiplatelet therapy when
long-term treatment is planned. We chose a 6-month period as a pragmatic time point to ascertain the
effects and side effects of more prolonged therapy. Reflecting the chronic nature of COPD, long-term
treatment regimens will be needed to derive cardiovascular protection and hence other time points
(⩾12 months) may have been equally important. Despite randomisation, the biomarker values were not
evenly distributed at baseline in our study. Nevertheless, we did not demonstrate any differences in
biomarker levels between baseline values and during follow-up in the different groups. This might also be
attributed to small sample size in our study.
Conclusion
Platelet response (the predefined cut-off of platelet inhibition measured using the Multiplate test) to
antiplatelet therapy with aspirin and ticagrelor was not observed in nearly one-third of patients in the
per-protocol analysis. Bruising is a common side-effect, but clinically significant bleeding is uncommon.
Some patients experience dyspnoea on ticagrelor, but this is mild or moderate in the majority of patients.
These findings support the high prothrombotic milieu in COPD patients where in addition to potent
antiplatelet therapy, an antithrombotic therapy might be beneficial in addressing the excess cardiovascular
morbidity and mortality warranting further investigation.
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